I've written several posts on pertussis
(whooping cough) and pertussis vaccines over the last four years. I started my position in communicable
disease epidemiology at the Tacoma-Pierce County Health Department at the beginning of the 2012 Washington State pertussis epidemic. Pertussis is a issue that has
demanded a lot of our time and attention ever since.
Historically, pertussis was thought of as a childhood
disease. We now recognize that immunity to pertussis, through immunization or
natural infection, wanes over time, and that the effectiveness of acellular
pertussis vaccines wanes much more quickly than immunity from whole-cell pertussis
vaccines. A case-control study reviewing data from the 2012 pertussis epidemic
in Washington State demonstrated that, for children who had received all
acellular pertussis vaccines, vaccine effectiveness was 73.1% within one year,
54.9% between one and two years, and 24.2% between two and three years (Acosta et al., 2015). Two studies of data from the 2010 pertussis epidemic in
California demonstrated that children who received one or more doses of
whole-cell pertussis vaccine were less likely to have polymerase chain reaction
(PCR)-confirmed pertussis than children who had received all acellular
pertussis vaccines (Klein et al., 2013; Witt et al., 2013).
The age distribution of pertussis cases in Pierce County in
2012 was similar to that in California in 2014 (Winter et al., 2014), with fewer cases at the ages at which pertussis vaccine
booster doses are scheduled and fewer cases and lower incidence of pertussis in
people born before 1997 who would have received at least one dose of whole-cell
pertussis vaccine as part of their primary series.
Infants too young to receive pertussis-containing vaccine
are at highest risk for complications and death from pertussis. During the 2012
epidemic, the incidence of pertussis in Pierce County and Washington State was
highest in children under one year of age. Of the 15 Pierce County residents
hospitalized for pertussis in 2012, 12 (80%) were under one year of age and 11
of those were under 6 months of age, too young to have received 3 doses of
DTaP.
In 2015, 5 Pierce County residents were hospitalized for
pertussis, three of whom were infants less than 2 months of age. Two of the
mothers of those babies did not receive the recommended dose of tetanus, diphtheria,
and acellular pertussis vaccine (Tdap) during pregnancy.
Case Series:
Case 1: Two-month-old girl with worsening cough admitted for
observation with PCR-confirmed pertussis. Her mother received Tdap during
pregnancy. While hospitalized, the infant had mild desaturations during
coughing fits which quickly resolved without intervention. The baby was
observed on the pediatric unit, not intensive care unit (ICU), and was
discharged home on day three.
Case 2: One-month-old girl admitted with repeated episodes
of desaturation and bradycardia. On the second day after admission, the baby
was intubated and mechanically ventilated with sedation and chemical paralysis.
She spent 8 days intubated, 11 days in the pediatric intensive care unit
(PICU), and was discharged to home on day 15. Her mother did not receive Tdap
during pregnancy.
Case 3: Three-week-old girl admitted after an episode of
choking cough, apnea and cyanosis. Although the obstetric care provider recommended
that her mother get a Tdap at the pharmacy, she did not receive one. The baby
spent 3 weeks in PICU and was discharged four weeks after admission.
Although this sample is not representative, it is notable
that the child whose mother received Tdap during pregnancy was not admitted to
the PICU and had the shortest length of stay.
Antibody titers in adults who receive Tdap also wane. Healy et al. (2013)
found that titers of pertussis-specific antibodies in cord blood from mothers
who had received Tdap before or early in pregnancy were unlikely to provide
adequate protection against infection for their newborn infants. In October
2012, the CDC's Advisory Committee on Immunization Practices (ACIP) recommended Tdap at 27 to 36 weeks of gestation with every pregnancy based on studies of
paired maternal and cord blood from women who received Tdap during pregnancy.
The American College of Obstetricians and Gynecologists (ACOG) and the American College of Nurse-Midwives support the ACIP recommendation.
Two studies conducted in the U.K. evaluated the
effectiveness of maternal Tdap at preventing pertussis in infants too young to
receive DTaP. Vaccine effectiveness was 93% for infants born to women who
received Tdap in the third trimester (Dabrera et al., 2015) and 90% for infants younger than 2 months whose mothers received Tdap
at least 1 week before birth (Amirthalingam et al., 2014).
Although estimates since the 2012 recommendation have not
yet been published, uptake of Tdap during pregnancy has been lower than
optimal. As part of a pilot project, the Washington State Department of Health
is currently collecting data on Tdap during pregnancy from hospitals in
selected counties, including Pierce. Data are preliminary, but, in 2014, less
than 50% of women who delivered at Pierce County hospitals had a dose of Tdap
during the pregnancy that was recorded in the hospitals' electronic medical
record. Administering Tdap during a prenatal visit is the most effective way to
ensure that a pregnant woman receives the dose. CDC recommends that providers
who do not stock vaccines in their offices make a "strong referral" for vaccination. Resources supporting immunizing pregnant
women are found on the ACOG,
CDC, and Tacoma-Pierce County Health Department websites.
References:
Acosta, A. M., DeBolt, C., Tasslimi, A., Lewis, M., Stewart,
L. K., Misgades, L. K., et al. (2015). Tdap vaccine effective in adolescents
during the 2012 Washington State pertussis epidemic. Pediatrics, 135(6). doi:10.1542/peds.2014-3358.
http://pediatrics.aappublications.org/content/135/6/981.long.
American College of Nurse-Midwives. (2014). Position
statement: immunization in pregnancy and p.ostpartum. http://midwife.org/ACNM/files/ACNMLibraryData/UPLOADFILENAME/000000000289/Immunization-in-Pregnancy-and-Postpartum-May-2014.pdf.
American College of Obstetrics and Gynecologists. (2013).
ACOG Committee Opinion No. 566: Update of immunization and pregnancy: tetanus,
diphtheria, and pertussis vaccination. Obstetrics
and Gynecology, 121(6). doi:10.1097/01.AOG.0000431054.33593.e3. http://www.acog.org/Resources-And-Publications/Committee-Opinions/Committee-on-Obstetric-Practice/Update-on-Immunization-and-Pregnancy-Tetanus-Diphtheria-and-Pertussis-Vaccination.
Amirthalingam, G., Andrews, N., Campbell, H., Ribeiro, S.,
Kara, E., Donegan, K., et al. (2014). Effectiveness of maternal pertussis vaccination
in England: an observational study. Lancet,
384(9953). doi:10.1016/S0140-6736(14)60686-3. http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(14)60686-3/fulltext.
Centers for Disease Control and Prevention. (2013). Updated
recommendations for use of tetanus toxoid, reduced diphtheria, and acellular
pertussis vaccine (Tdap) in pregnant women – Advisory Committee on Immunization
Practices (ACIP), 2012. Morbidity and
Mortality Weekly Report, 62(7), 131-135. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6207a4.htm.
Dabrera, G., Amirthalingam, G., Andrews, N., Campbell, H.,
Ribeiro, S., Kara, E., et al. (2015). A case-control study to estimate the
effectiveness of maternal pertussis vaccination in protecting newborn infants
in England and Wales, 2012-2013. Clinical
Infectious Diseases, 60(3). doi:10.1093/cid/ciu821. http://cid.oxfordjournals.org/content/60/3/333.abstract.
Edwards, K. M. & Decker, M. D. (2013). Pertussis
vaccines. In S. A. Plotkin, W. A. Orenstein, & P. A. Offit (Eds.) Vaccines
(6th Ed.). [Electronic version]. Elsevier.
Healy, C. M., Rench, M. A., & Baker, C. J. (2013).
Importance of timing of maternal combines tetanus, diphtheria, and acellular
pertussis (Tdap) immunization and protection of young infants. Clinical Infectious Diseases, 56(4).
doi:10.1093/cid/cis923. http://cid.oxfordjournals.org/content/56/4/539.long.
Klein, N. P., Bartlett, J., Fireman, B., Rowhani-Rahbar, A.
& Baxter, R. (2013). Comparative effectiveness of acellular versus
whole-cell pertussis vaccines in teenagers. Pediatrics,
131(6). doi:10.1542/peds.2012-3836. http://pediatrics.aappublications.org/content/131/6/e1716.long.
Winter, K., Harriman, K., Zipprich, J., Schechter, R.,
Talarico, J., Watt, J., et al. (2012). California pertussis epidemic, 2010. Journal of Pediatrics, 161(6).
doi:10.1016/j.jpeds.2012.05.041. http://www.jpeds.com/article/S0022-3476(12)00558-6/abstract.
Witt, M. A., Arias, L., Katz, P. H., Truong, E. T., &
Witt, D. J. (2013). Reduced risk of pertussis among persons ever vaccinated
with whole cell pertussis vaccine compared to recipients of acellular pertussis
vaccines in a large US cohort. Clinical
Infectious Diseases, 56(9). doi:10.1093/cid/cit046. http://cid.oxfordjournals.org/content/56/9/1248.long.